Eosinophil-Driven Diseases (EDDs)

Expanding the reach of our medicines to address unmet needs

Our commitment to eosinophil-driven diseases

We are committed to developing medicines for eosinophil-driven diseases (EDDs) where there is a clear unmet treatment need, with the ambition to improve the health outcomes and lives of millions of patients worldwide who face these debilitating, potentially fatal illnesses.1,2

EDDs are inflammatory illnesses in which elevated eosinophils are a direct cause or are thought to play a critical role.3 They include eosinophilic esophagitis, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome and some types of nasal polyposis, severe asthma and chronic obstructive pulmonary disease. 

Some EDDs have limited or no approved treatment options, creating a significant unmet need for innovative medicines. 

Patient Portraits

Types of eosinophil-driven diseases

We are currently investigating the potential within our biologics portfolio to treat inflammatory, EDDs where patients could benefit from innovative medicines.

Join us

At AstraZeneca, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. Join us and help deliver life-changing medicines. Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals. 


1.     American Partnership for Eosinophilic Disorders. Eosinophilic Granulomatosis with Polyangiitis (EGPA). Accessed 20 November 2018. https: apfed.org/about-ead/eosinophilic-granulomatosis-with-polyangiitis/.

2.     American Partnership for Eosinophilic Disorders. Hypereosinophilic Syndromes. Accessed 16 September 2019. https://apfed.org/about-ead/hypereosinophilic-syndrome/.

3.     American Partnership for Eosinophilic Disorders. What is an eosinophil associated disease? Accessed 16 September 2019. https://apfed.org/about-ead/what-is-an-eosinophil-associated-disease/

4.     American Partnership for Eosinophilic Disorders. EoE. Accessed 16 September 2019. https://apfed.org/about-ead/egids/eoe/.

5.     Baldini C, Talarico R, Della Rossa A, Bombardieri S. Clinical Manifestations and Treatment of Churg-Strauss Syndrome. Rheum Dis Clin N Am. 2010; 36: 527-543.

6.     American Academy of Allergy Asthma & Immunology. Nasal Polyps. Accessed 16 September 2019. https://aaaai.org/conditions-and-treatments/conditions-dictionary/Nasal-Polyps

Veeva ID: Z4-12506

Date of next review: 04/09/2021